Revenue
2019
2020
NextCure, Inc. (NXTC)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $22.4M | $6.3M | — |
| Research & development | $44.9M | $41.5M | $47.9M | $54.2M | $50.2M | $46.6M | $34.2M | $19.8M |
| Operating expenses | $57.6M | $59.7M | $67.6M | $75.9M | $70.8M | $63.6M | $43.8M | $23.2M |
| Operating income | −$57.6M | −$59.7M | −$67.6M | −$75.9M | −$70.8M | −$41.2M | −$37.5M | −$23.2M |
| EBITDAderived | −$55.4M | −$56.8M | −$63.9M | −$71.8M | −$66.5M | −$37.8M | −$34.8M | −$21.5M |
| Net income | −$55.8M | −$55.7M | −$62.7M | −$74.7M | −$69.4M | −$36.6M | −$33.7M | −$22.8M |
| Basic EPSper diluted share | -$19.65 | -$23.88 | -$2.25 | -$2.69 | -$2.51 | -$1.33 | -$2.15 | -$16.64 |
| Diluted EPSper diluted share | -$19.65 | -$23.88 | -$2.25 | -$2.69 | -$2.51 | -$1.33 | -$2.15 | -$16.64 |